Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study
IntroductionIn COVID-19 patients on mechanical ventilation, VAP from Acinetobacter baumannii remains a crucial risk factor for death. Antibiotic resistance represents an important problem in treating this infection. This study aims to describe the evolution of the superinfection from PDR Acinetobact...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.910031/full |
| _version_ | 1811336354502541312 |
|---|---|
| author | Erika Casarotta Elisa Bottari Sara Vannicola Rachele Giorgetti Roberta Domizi Andrea Carsetti Andrea Carsetti Elisa Damiani Elisa Damiani Claudia Scorcella Vincenzo Gabbanelli Simona Pantanetti Benedetto Marini Abele Donati Abele Donati Erica Adrario Erica Adrario |
| author_facet | Erika Casarotta Elisa Bottari Sara Vannicola Rachele Giorgetti Roberta Domizi Andrea Carsetti Andrea Carsetti Elisa Damiani Elisa Damiani Claudia Scorcella Vincenzo Gabbanelli Simona Pantanetti Benedetto Marini Abele Donati Abele Donati Erica Adrario Erica Adrario |
| author_sort | Erika Casarotta |
| collection | DOAJ |
| description | IntroductionIn COVID-19 patients on mechanical ventilation, VAP from Acinetobacter baumannii remains a crucial risk factor for death. Antibiotic resistance represents an important problem in treating this infection. This study aims to describe the evolution of the superinfection from PDR Acinetobacter baumannii in patients with acute respiratory failure from SARS-CoV-2 infection admitted to ICU and compare the impact of two different antibiotic strategies on microbiological negativization.MethodsSingle-center observational retrospective study, including patients admitted to our ICU from March 2020 to May 2021 for acute respiratory failure from SARS-CoV-2 infection who developed PDR Acinetobacter baumannii superinfection. Clinical data at ICU admission were collected, as well as the timing of isolation of Acinetobacter baumannii, its resistance profile, the site of infection, and the antibiotic therapy.ResultsOf the 32 patients enrolled, 10 patients (31.2%) were treated with the combination of high-dose ampicillin/sulbactam, high-dose tigecycline, intravenous and inhaled colistin (Protocol), the other 22 (68.8%) were treated with the combination of two antibiotics (Control). Of the 10 patients in the Protocol group, 8 patients (80%) received also fosfomycin. All patients (100%) in the Protocol group had microbiological negativization, while in the Control group microbiological negativization was observed in 8 (36.4%) patients, p < 0.01.ConclusionOur report shows microbiological negativization in all patients treated with the combination therapy of nebulized and intravenous colistin, high-dose tigecycline, and high-dose ampicillin/sulbactam. This combination of antibiotics seems to be a useful alternative when other treatments are not available or fail. |
| first_indexed | 2024-04-13T17:38:13Z |
| format | Article |
| id | doaj.art-da14efad40b24891ac7a016fe8caa07d |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T17:38:13Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-da14efad40b24891ac7a016fe8caa07d2022-12-22T02:37:17ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.910031910031Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective StudyErika Casarotta0Elisa Bottari1Sara Vannicola2Rachele Giorgetti3Roberta Domizi4Andrea Carsetti5Andrea Carsetti6Elisa Damiani7Elisa Damiani8Claudia Scorcella9Vincenzo Gabbanelli10Simona Pantanetti11Benedetto Marini12Abele Donati13Abele Donati14Erica Adrario15Erica Adrario16Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyDepartment of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, ItalyAnesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, ItalyIntroductionIn COVID-19 patients on mechanical ventilation, VAP from Acinetobacter baumannii remains a crucial risk factor for death. Antibiotic resistance represents an important problem in treating this infection. This study aims to describe the evolution of the superinfection from PDR Acinetobacter baumannii in patients with acute respiratory failure from SARS-CoV-2 infection admitted to ICU and compare the impact of two different antibiotic strategies on microbiological negativization.MethodsSingle-center observational retrospective study, including patients admitted to our ICU from March 2020 to May 2021 for acute respiratory failure from SARS-CoV-2 infection who developed PDR Acinetobacter baumannii superinfection. Clinical data at ICU admission were collected, as well as the timing of isolation of Acinetobacter baumannii, its resistance profile, the site of infection, and the antibiotic therapy.ResultsOf the 32 patients enrolled, 10 patients (31.2%) were treated with the combination of high-dose ampicillin/sulbactam, high-dose tigecycline, intravenous and inhaled colistin (Protocol), the other 22 (68.8%) were treated with the combination of two antibiotics (Control). Of the 10 patients in the Protocol group, 8 patients (80%) received also fosfomycin. All patients (100%) in the Protocol group had microbiological negativization, while in the Control group microbiological negativization was observed in 8 (36.4%) patients, p < 0.01.ConclusionOur report shows microbiological negativization in all patients treated with the combination therapy of nebulized and intravenous colistin, high-dose tigecycline, and high-dose ampicillin/sulbactam. This combination of antibiotics seems to be a useful alternative when other treatments are not available or fail.https://www.frontiersin.org/articles/10.3389/fmed.2022.910031/fullAcinetobacter baumanniisuperinfectionSARS-CoV-2acute respiratory failureantibiotics |
| spellingShingle | Erika Casarotta Elisa Bottari Sara Vannicola Rachele Giorgetti Roberta Domizi Andrea Carsetti Andrea Carsetti Elisa Damiani Elisa Damiani Claudia Scorcella Vincenzo Gabbanelli Simona Pantanetti Benedetto Marini Abele Donati Abele Donati Erica Adrario Erica Adrario Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study Frontiers in Medicine Acinetobacter baumannii superinfection SARS-CoV-2 acute respiratory failure antibiotics |
| title | Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study |
| title_full | Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study |
| title_fullStr | Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study |
| title_full_unstemmed | Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study |
| title_short | Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study |
| title_sort | antibiotic treatment of acinetobacter baumannii superinfection in patients with sars cov 2 infection admitted to intensive care unit an observational retrospective study |
| topic | Acinetobacter baumannii superinfection SARS-CoV-2 acute respiratory failure antibiotics |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.910031/full |
| work_keys_str_mv | AT erikacasarotta antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT elisabottari antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT saravannicola antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT rachelegiorgetti antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT robertadomizi antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT andreacarsetti antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT andreacarsetti antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT elisadamiani antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT elisadamiani antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT claudiascorcella antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT vincenzogabbanelli antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT simonapantanetti antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT benedettomarini antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT abeledonati antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT abeledonati antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT ericaadrario antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy AT ericaadrario antibiotictreatmentofacinetobacterbaumanniisuperinfectioninpatientswithsarscov2infectionadmittedtointensivecareunitanobservationalretrospectivestudy |